ENHERTU® Plus Pertuzumab reduced the risk of disease progression or death by 44% xersus THP as first-line therapy in patients with HER2 positive metastatic breast cancer in DESTINYBreast09 Phase 3 trial

CAR-T Digest - August 2020

Weekly Digest - June 2025

02 June 2025: ENHERTU plus Pertuzumab reduced the risk of disease progression or death by 44% versus THP as first-line therapy in patients with HER2 positive metastatic breast cancer in DESTINYBreast09 Phase 3 trial

ENHERTU (Trastuzumab deruxtecan) plus pertuzumab significantly improved progression-free survival (PFS) over standard THP therapy, reducing the risk of progression or death by 44% and median PFS was 40.7 vs. 26.9 months
The confirmed ORR was higher with ENHERTU + pertuzumab (85.1%) versus THP (78.6%), and median duration of response exceeded 3 years (39.2 months vs. 26.4 months)
DESTINY-Breast09 trial suggests ENHERTU + pertuzumab may become the new first-line standard of care for HER2+ metastatic breast cancer, with nearly double the complete responses and prolonged PFS
This is the first trial in more than a decade to demonstrate an improvement in outcomes in the first-line setting for a broad population of patients with HER2 positive metastatic breast cancer